Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ILLUMINATE

Financiado

Cerrado

INCREASING LUTETIUM PRODUCTION WHILE LEVERAGING METABOLIC IMAGING TO ENHANCE TH...

INCREASING LUTETIUM PRODUCTION WHILE LEVERAGING METABOLIC IMAGING TO ENHANCE THERANOSTICS EFFECTIVENESS Selective targeting of therapy with antibody-radioisotope combinations have led to major advances in treating cancers that are resistant to common therapies, such as castrate-resistant prostate cancer. Adding Lutetium-177-PSMA (Lu... ver más

31/03/2029

Líder desconocido

19M€

Presupuesto del proyecto: 19M€

Líder del proyecto Líder desconocido

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-02

HORIZON-JU-IHI-2023-05-03: Improved prediction, detection, and... Expected Impact:Patients will be offered accelerated access to the healthcare system through improve...

I+D

Cerrada

0% 61% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

PHILIPS MEDICAL SYSTEMS NEDE...

PHILIPS GMBH

SYNLAB SDN SRL

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 54 meses Fecha Inicio: 2024-09-02
Fecha Fin: 2029-03-31

Líder del proyecto Líder desconocido

Presupuesto del proyecto 19M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Selective targeting of therapy with antibody-radioisotope combinations have led to major advances in treating cancers that are resistant to common therapies, such as castrate-resistant prostate cancer. Adding Lutetium-177-PSMA (Lu-177-PSMA) to standard care significantly prolongs survival. However, the increased use of Lu-177-based therapies has resulted in an increased demand for this isotope, leading to shortage risks.In addition, despite the success of Lu-177-treatment, ~30% of patients do not benefit from treatment, but do suffer from side-effects. ILLUMINATE, will improve the availability and use of theranostics across its value chain by taking a hybrid approach: 1) Imaging capabilities will be improved by implementing novel, broadly applicable, scalable and highly effective Metabolic Magnetic Resonance Imaging (MeMRI), which are expected to give better and faster insight into treatment responses, allowing better patient stratification and treatment personalisation; 2) The availability of Lu-177 will be fortified by improving its manufacturing process, and by developing sustainable production methods to help meet the general need for radio-isotope based therapies and increase EU autonomy. The ILLUMINATE consortium (industries Philips, NRG, Bracco, TeslaDC, Wavetronica, Lygature, SDN, EuroBioImaging, and the Univerisities of Torino, Lund, Amsterdam UMC, Klinik Essen, coordinated by UMC Utrecht) uses the example of Lu-177-PSMA as a showcase clinical trial in 150 patients for broadly applicable innovative technologies in the field of theranostics and radioisotope manufacturing for oncology.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores